Project Grant R43TR005911
Award Date 9/15/25
Completion Date 9/14/26
Dollars Obligated $349K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
- This $378,899.00 federal Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), aims to expand the genetic code and improve the drug-likeness of hits generated through mRNA display technology. The key objectives are: Leveraging hyperaccurate ribosomes and engineered tRNAs to move closer to a one codon-one amino acid paradigm, thereby enhancing the diversity of macrocyclic peptides that can be...
- This Project Grant award from the National Center for Advancing Translational Sciences (NCATS), under CFDA Program 93.350, provides $329,272 to Capienda Biotech, LLC to develop a high-throughput kinetic system for small-molecule drug discovery. The goal is to create an innovative instrument that can rapidly characterize the binding kinetics of compounds targeting human cyclin-dependent kinases, which are important oncology targets. This will help medicinal chemists identify drug candidates...
- This federal Project Grant award of $322,388.00 from the National Center for Advancing Translational Sciences (NCATS), under CFDA 93.350, will support the "Production of Stimulated Emission-Encoded Beads for Large Molecular Library Generation" at Spectral Therapeutics, Inc. in California. The project aims to develop an optical-encoded library technology capable of encoding diverse molecular libraries and decoding them instantaneously during assay readout. The technology will involve...
- This Project Grant award of $404,032 from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), aims to develop a machine learning-powered platform for the discovery of peptide ligands for peptide-drug conjugates (PDCs). The key objective is to create a next-generation peptide discovery system capable of identifying PDC leads within 3 months. The platform will utilize a peptide array designed for enhanced protease...
- This Project Grant award of $1,640,169 from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training program (CFDA 93.859) supports Synvivia, Inc.'s development of a platform to identify cyclic peptides that can increase the yield and quality of adeno-associated virus (AAV) vectors for gene therapy manufacturing. The key products and services to be delivered include: Demonstrating that Synvivia's cyclic peptide discovery library contains compounds that...
- This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $350,000 in funding to Cisterna Biologics, Inc. to develop a novel mRNA production and purification process. The key objectives are to: Optimize psychrophilic (cold-adapted) RNA polymerases and synthetic promoters to minimize contaminants in mRNA synthesis, improving safety and efficacy for therapeutic use. Implement...
- The National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health, awarded a $349,746 Project Grant to Cisterna Biologics, Inc., a biotechnology company based in Oceanside, California. The goal of this 1-year Phase I SBIR grant is to develop an innovative platform for synthesizing high-quality, purified mRNA with minimal contaminants such as double-stranded RNA, long RNA, and short truncated RNA. These impurities can provoke immune responses and...
- This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $303,445 to Endura Therapeutics Inc. aims to develop a next-generation sequencing platform for discovering small molecules that target RNA. The project addresses two key challenges: demonstrating that small molecules can modulate protein expression by binding to messenger RNA, and creating a high-throughput screening method to identify such molecules and their optimal RNA targets....
- This $419,398 Project Grant award, funded by the National Center for Advancing Translational Sciences (NCATS) CFDA Program 93.350, is supporting research to accelerate the development and delivery of oligonucleotide therapeutics (ONTs). The project aims to address the key barrier of biological membrane permeability that limits the ability of large, charged ONT molecules to reach their therapeutic targets within cells. The research at the University of California, Irvine will explore novel...
- This $380,337 federal Project Grant was awarded by the National Cancer Institute (NCI), under the Cancer Biology Research program (CFDA 93.396), to the University of Washington on March 1, 2025. The grant supports research to develop improved algorithms for optimizing mRNA sequences to enhance the expression and tissue targeting of mRNA cancer therapies. The project aims to combine machine learning and massively parallel reporter assays to build predictive models relating mRNA sequence to...